Some of Christine Blasey's publications
1.
A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction.
Blasey CM, Debattista C, Roe R, Block T, Belanoff JK.
Contemp Clin Trials. 2009 Jul;30(4):284-8. doi: 10.1016/j.cct.2009.03.001. Epub 2009 Mar 24. Erratum in: Contemp Clin Trials. 2010 Jan;31(1):134. Contemp Clin Trials. 2009 Sep;30(5):497.
PMID: 19318138
Similar articles
Select item 21694614
2.
Efficacy and safety of mifepristone for the treatment of psychotic depression.
Blasey CM, Block TS, Belanoff JK, Roe RL.
J Clin Psychopharmacol. 2011 Aug;31(4):436-40. doi: 10.1097/JCP.0b013e3182239191.
PMID: 21694614
Similar articles
Select item 16889757
3.
Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.
DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G.
Biol Psychiatry. 2006 Dec 15;60(12):1343-9. Epub 2006 Aug 4.
PMID: 16889757
Similar articles
Select item 16782211
4.
The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.
Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK.
Behav Brain Res. 2006 Aug 10;171(2):225-9. Epub 2006 Jun 19.
PMID: 16782211
Similar articles
Select item 20339369
5.
Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Gross C, Blasey CM, Roe RL, Belanoff JK.
Obesity (Silver Spring). 2010 Dec;18(12):2295-300. doi: 10.1038/oby.2010.51. Epub 2010 Mar 25.
PMID: 20339369 Free Article
Similar articles
Select item 19888560
6.
Mifepristone treatment of olanzapine-induced weight gain in healthy men.
Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK.
Adv Ther. 2009 Oct;26(10):959-69. doi: 10.1007/s12325-009-0070-1. Epub 2009 Nov 4.
PMID: 19888560
Similar articles
Select item 21269600
7.
Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.
Belanoff JK, Blasey CM, Clark RD, Roe RL.
Eur J Pharmacol. 2011 Mar 25;655(1-3):117-20. doi: 10.1016/j.ejphar.2011.01.019. Epub 2011 Jan 24.
PMID: 21269600
Similar articles
Select item 16673835
8.
A randomized trial of the efficacy of group therapy in changing viral load and CD4 counts in individuals living with HIV infection.
Belanoff JK, Sund B, Koopman C, Blasey C, Flamm J, Schatzberg AF, Spiegel D.
Int J Psychiatry Med. 2005;35(4):349-62.
PMID: 16673835
Similar articles
Select item 23131342
9.
Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat.
Hunt HJ, Ray NC, Hynd G, Sutton J, Sajad M, O'Connor E, Ahmed S, Lockey P, Daly S, Buckley G, Clark RD, Roe R, Blasey C, Belanoff J.
Bioorg Med Chem Lett. 2012 Dec 15;22(24):7376-80. doi: 10.1016/j.bmcl.2012.10.074. Epub 2012 Oct 23.
PMID: 23131342
Similar articles
Select item 21811679
10.
Selective Glucocorticoid Receptor (GR-II) Antagonist Reduces Body Weight Gain in Mice.
Asagami T, Belanoff JK, Azuma J, Blasey CM, Clark RD, Tsao PS.
J Nutr Metab. 2011;2011:235389. doi: 10.1155/2011/235389. Epub 2011 Jul 28.
PMID: 21811679 Free PMC Article
Similar articles
Select item 20518810
11.
Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.
Belanoff JK, Blasey CM, Clark RD, Roe RL.
Diabetes Obes Metab. 2010 Jun;12(6):545-7. doi: 10.1111/j.1463-1326.2009.01185.x.
PMID: 20518810
Similar articles
Select item 17935144
12.
Supportive-expressive group therapy for primary breast cancer patients: a randomized prospective multicenter trial.
Classen CC, Kraemer HC, Blasey C, Giese-Davis J, Koopman C, Palesh OG, Atkinson A, Dimiceli S, Stonisch-Riggs G, Westendorp J, Morrow GR, Spiegel D.
Psychooncology. 2008 May;17(5):438-47.
PMID: 17935144 Free PMC Article
Similar articles